Pacritinib for the Treatment of Patients with Myelofibrosis
John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses studies investigating pacritinib for the treatment of myelofibrosis.
Ruxolitinib Demonstrates Safety, Efficacy in Myelofibrosis, Expanded Access Trial Confirms
Worldwide clinical experience with the JAK1/2 inhibitor ruxolitinib in patients with myelofibrosis has yielded safety and efficacy data similar to results of a pivotal randomized trial.
Consistent Survival Benefit Seen With Ruxolitinib in Myelofibrosis
Treating patients with intermediate/high-risk myelofibrosis with the Janus kinase inhibitor ruxolitinib long-term demonstrated improved survival, pooled data from 2 randomized trials showed.
Patients with MPNs Have High Symptom Burden, Survey Shows
An international patient survey showed patients with myeloproliferative disorders have a high symptom burden that significantly affects emotional status, quality of life, and functional ability.
2 Commerce Drive Cranbury, NJ 08512